- Home
- CATX vs HURA Comparison
CATX vs HURA Comparison
Compare CATX & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CATX | HURA |
|---|---|---|
| Founded | 1983 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.8M | 131.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CATX | HURA |
|---|---|---|
| Price | $2.71 | $1.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $11.56 | $11.50 |
| AVG Volume (30 Days) | ★ 1.9M | 447.0K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,075,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.60 | $0.97 |
| 52 Week High | $5.39 | $5.99 |
Technical Indicators
Market Signals| Indicator | CATX | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 58.27 | 25.42 |
| Support Level | $2.07 | $0.97 |
| Resistance Level | $2.39 | $2.02 |
| Average True Range (ATR) | 0.18 | 0.19 |
| MACD | 0.10 | -0.09 |
| Stochastic Oscillator | 75.60 | 4.47 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.